(Q27851708)

13 November 2016

title

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer (English)

1 reference

Erratum: Corrigendum: Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

PubMed

PubMed publication ID

13 November 2016

0 references

1 reference

1 reference

1 reference

corrigendum / erratum

1 reference

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1038/NM0912-1445B

15

Heinz Himmelbauer

0 references

Marta Crespo

object named as

Marta Crespo

4

0 references

Ana Rovira

object named as

Ana Rovira

17

0 references

author name string

Clara Montagut

1

0 references

Alba Dalmases

2

0 references

Beatriz Bellosillo

3

0 references

Silvia Pairet

5

0 references

Mar Iglesias

6

0 references

Marta Salido

7

0 references

Manuel Gallen

8

0 references

Scot Marsters

9

0 references

Siao Ping Tsai

10

0 references

André Minoche

11

0 references

Somasekar Seshagiri

12

0 references

Seshagiri Somasekar

13

0 references

Sergi Serrano

14

0 references

Joaquim Bellmunt

16

0 references

Jeff Settleman

18

0 references

Francesc Bosch

19

0 references

Joan Albanell

describes a project that uses

20

0 references

language of work or name

English

0 references

publication date

22 January 2012

0 references

1 reference

18

0 references

issue

2

0 references

page(s)

221-3

0 references

0 references

0 references

0 references

0 references

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 April 2017

1 reference

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 April 2017

1 reference

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 April 2017

1 reference

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FNM.2609

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FNM.2609